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(Warren et al., 2010). Because the exog-
enously administered RNA molecules 
are rapidly degraded, the DNA back-
bone of the reprogrammed cells remains 
intact and is indistinguishable from that 
of the original wild-type cells. Finally, 
the use of iPS cells to treat heritable skin 
diseases will require transduction of the 
missing or nonfunctional gene to the 
cells (such as type VII collagen into iPS 
cells generated from patients with RDEB) 
for patients who do not display revertant 
mosaicism. Here again, the question of 
carcinogenesis, even if a hypothetical 
possibility, has been raised when ret-
roviral vectors have been used to insert 
the transgene. Along these lines, gene-
correction strategies, such as zinc-finger 
nuclease technology, have emerged as 
viable alternatives for the repair of muta-
tions in iPS cells (Urnov et al., 2010).
It is clear at this point that iPS cells 
can provide a useful model for studying 
the mechanisms of diseases, and these 
cell systems can be used for large-scale 
screens in the development of candidate 
drugs. Novel technologies relating to iPS 
cells are rapidly being developed (Csete, 
2010; Warren et al., 2010), and the three 
papers highlighted above mark a signifi-
cant milestone in skin biology because 
they demonstrate differentiation of both 
human and mouse iPS cells into kerati-
nocytes. Refinements in the generation of 
such cells may provide treatment options 
for heritable skin diseases such as RDEB 
sooner than we realize.
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Pulling RANK: Are Some Melanoma 
Cells More Malignant than Others?
Mark Shackleton1,2
Cellular heterogeneity is a frequently noted feature of melanoma. As reported in 
this issue, Kupas et al. identified heterogeneous expression of receptor activator 
of nuclear factor-κB (RANK) in melanoma cells in tumors and peripheral blood 
from patients. Increased expression of RANK was associated with the presence 
of metastatic disease and increased tumorigenicity in melanoma cells, raising the 
possibility that RANK signaling contributes to melanoma progression.
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least some melanoma cells that enter the 
circulation after dislodging from tumors 
must not only harbor intrinsic malignant 
Clinical Implications
•  Generation of iPS cells provides an essentially unlimited source of cells 
with the potential to differentiate into any cell type in the body.
•  iPS cells have been shown to differentiate into keratinocytes with the 
capacity to form skin-like structures.
•  iPS cells may provide a personalized, patient-specific approach to treat 
skin diseases such as EB.
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potential but also be able to survive the 
rigors of intravascular transit. However, 
it is not known whether the abilities to 
metastasize, survive, and maintain malig-
nant potential in the blood are confined 
to distinct populations of cancer cells or 
whether any cancer cell has these abili-
ties. Also, it is not known whether some 
melanoma cells that have malignant 
potential in tumors irreversibly lose this 
potential once they enter the circula-
tion. The study by Kupas et al. (this issue) 
considers these matters.
The question of whether melanoma 
cells have heterogeneous potentials to 
propagate disease in patients remains 
both important and contentious. On 
one hand, evidence has been presented 
to support the possibility that mela-
noma cells within tumors are hierarchi-
cally organized into tumorigenic cells 
and pheno typically distinct non-/less 
tumorigenic cells that derive from the 
tumorigenic cell fraction (Boiko et al., 
2010; Monzani et al., 2007; Schatton 
et al., 2008). These studies identified 
cell surface markers (CD271, CD133, 
and ABCB5, respectively) that defined, 
within patient tumors, melanoma cell 
populations enriched for tumor-forming 
potential in immunodeficient mice. The 
identification of markers that distinguish 
more and less malignant melanoma cells 
within tumors is important because it pro-
vides the opportunity to study and target 
therapeutically the most malignant cells.
On the other hand, there is compelling 
evidence that melanomas are not hierar-
chically organized, indicating that target-
ing rare and/or phenotypically distinct 
cells will not provide meaningful clinical 
benefit. This conclusion is supported by 
studies that used either transplantation 
of mouse melanoma cells into syngeneic 
recipients (Held et al., 2010) or human 
melanoma cells in a modified assay high-
ly permissive for revealing tumorigenic 
potential (Quintana et al., 2008, 2010). 
For example, in the human studies in 
which melanoma cells were transplanted 
into immunocompromised NOD/SCID 
IL2Rgnull (NSG) mice, neither ABCB5, 
CD271, nor CD133 expression defined a 
subpopulation of cells that had enriched 
tumorigenic potential and was hierarchi-
cally related to the marker-negative cell 
fraction (Quintana et al., 2008, 2010). 
Differences observed in tumorigenesis 
assays in the malignant behaviors of phe-
notypically distinct melanoma cells can 
thus result from the assays themselves 
rather than from intrinsic differences 
between cells (Shackleton, 2010).
The data presented by Kupas and col-
leagues (2011) raise the possibility that 
expression of receptor activator of nuclear 
factor-κB (RANK) in melanoma cells may 
be associated with increased malignant 
potential. In this study, the tumorigenic 
potential of cells expressing melanoma-
associated markers and separated 
according to RANK expression was tested 
after isolation by flow cytometry of cells 
from the peripheral blood of melanoma 
patients. Purified RANK- and RANK+ cells 
were injected into NSG mice; after 50 
days, tumors were found only in mice 
injected with RANK+ cells. Consistent 
with the associated findings of increased 
RANK-expressing melanoma cells in the 
peripheral blood and in tumors of patients 
with metastatic disease compared with 
patients with early-stage disease, these 
data raise the possibility that expression 
of RANK in melanoma cells is associated 
with increased malignant behavior that 
contributes to disease progression.
In light of the potential importance of 
these data, careful evaluation is required. 
The tumorigenicity studies of melanoma 
cells isolated from peripheral blood were 
performed with transplants of far greater 
numbers (25,000) of melanoma cells 
than are required to generate xenografted 
tumors from cells derived from whole 
melanomas (in which the frequency of 
tumorigenic cells is, on average, one in 
four cells (Quintana et al., 2008)). It is 
not clear why such large numbers of cells 
were used to test tumor formation in NSG 
mice from purified RANK- and RANK+ 
populations. If the efficiency of tumor 
formation is reduced compared with pre-
vious studies in the assay used by Kupas 
and colleagues (2011), it is possible that 
the failure of RANK- cells to form tumors 
could reflect relative assay inefficiency 
(possibly resulting from the short (50-
day) follow-up after cell transplantation 
and the absence of pretransplant mixing 
of cells in Matrigel) rather than a lack of 
tumorigenic potential in RANK- cells. 
Alternatively, it is also possible that most 
melanoma cells lose tumorigenic poten-
tial while transiting in peripheral blood, 
despite the fact that they possess such 
potential in whole tumors. To address 
this, xenotransplantation engraftment 
efficiencies could be compared between 
melanoma cells obtained from periph-
eral blood and from whole tumors in the 
same patient. It will also be important to 
determine in optimized tumorigenesis 
assays whether RANK- melanoma cells in 
whole tumors have reduced tumorigenic 
potential compared with RANK+ cells.
Another issue relating to the data pre-
sented by Kupas et al. is the method used 
to isolate live, circulating melanoma 
cells from peripheral blood. The ability 
to study the biology of freshly isolated, 
circulating tumor cells (CTCs) in patients 
with melanoma should provide impor-
tant insights into the metastatic process. 
Laudably, Kupas and colleagues provide 
one of the first descriptions of a method 
to accomplish this, using a combination 
of bead-enrichment strategies and direct 
positive selection by flow cytometry. 
However, it is not clear whether this 
method selects all circulating melanoma 
cells or only some. The ideal antibod-
ies for melanoma CTC isolation will be 
raised against epitopes that are 100% 
expressed on all melanoma cells in 
every tumor (or blood sample) and are 
highly specific for melanoma cells rath-
er than nonmelanoma cells. Because 
melanoma is a highly heterogeneous 
disease, characterized by variable and 
unstable expression of numerous mark-
ers (Quintana et al., 2010), melanoma 
cell–isolation methods that rely on anti-
bodies must be carefully tested in many 
patients to determine their reliability 
and generalizability. At a minimum, this 
should include evaluation for the pres-
ence of melanoma-specific transcripts 
in each of the separated cell fractions at 
each step of the isolation procedure. To 
improve our understanding of the biolo-
gy of metastasis by studying CTCs, it will 
be important to develop and validate 
robust methods that isolate the full 
spectrum of these cells in patients.
| RANK identified the metastatic potential of melanoma cells when 
injected into mice.
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One implication of the report by Kupas 
et al. (2011) is the possibility that inhibit-
ing RANK-mediated signaling may be a 
rational therapeutic strategy for improving 
the treatment of patients with or at high 
risk of developing metastatic melanoma. 
To date, trials in cancer patients of inhibi-
tion of RANK signaling by RANK ligand 
sequestration have suggested clinical ben-
efit in the management of bone metastasis, 
consistent with the known role of RANK 
in mediating bone remodel ing (Stopeck 
et al., 2010). However, direct antitumor 
effects of this therapy have yet to be dem-
onstrated. The work of Kupas and col-
leagues raises the question of whether 
RANK signaling mediates melanoma cell 
metastasis and provides a basis for devel-
oping preclin ical models to test this.
One important determinant of the effec-
tiveness of anti-RANK therapies will relate 
to whether RANK+ and RANK- melanoma 
cells are hierarchically related in a manner 
consistent with a cancer stem cell model. If 
RANK+ melanoma cells were able to pro-
duce both more RANK+ cells and RANK- 
melanoma cells, but RANK- cells did not 
produce RANK+ cells, then therapeutically 
eliminating or inhibiting the RANK+ cell 
fraction in patients would be expected 
to confer clinical benefit. However, if 
melanoma cells can gain and lose RANK 
expression in a plastic manner, as has been 
described for numerous melanoma cell 
markers (Quintana et al., 2010; Roesch 
et al., 2010), then all melanoma cells will 
need to be eliminated in effective treatment 
strategies, regardless of RANK expression.
The treatment of advanced melanoma 
is currently undergoing revolutionary 
change with the demonstration that anti-
CTLA-4 antibodies prolong life expectancy 
in a significant proportion of patients (Hodi 
et al., 2010). Even greater expectations 
of clinical benefit are held for inhibitors 
of mutated BRAF, which in early-phase 
studies have produced remarkably high 
anti tumor response rates (Flaherty et al., 
2010). However, it is sobering to reflect 
|Expression of RANK  by melanoma cells  may lead to new 
therapeutic strategies. 
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The Influence of Flightless I: 
Regeneration versus Wound Healing
Maria I. Morasso1
The molecular mechanisms involved in organ regeneration has biomedical 
implications in regenerative medicine. In this issue, Waters et al. demonstrate 
that levels of the established negative wound healing factor Flightless I (Flii) 
modulate the hair follicle’s capacity to regenerate a fiber-forming bulb after 
amputation. Still to be investigated are the specific pathways through which Flii 
influences regeneration as compared with wound healing.
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An organism’s regenerative capacity 
varies by species and developmental 
stage. Although mammalian tissues 
have limited regenerative capacity 
when compared with the epimorphic 
regeneration seen in urodeles (Endo 
that the majority of patients treated 
with anti-CTLA-4 therapy received no 
overt benefit and that the median dura-
tion of response to BRAF inhibition in 
published studies has been less than 12 
months. Although further development 
of these therapies is a high priority, it will 
be important to define additional thera-
peutic targets in melanoma cells in order 
to expand our armamentarium against 
this disease and provide multipronged 
treatment approaches. It is premature to 
conclude that the RANK signaling path-
way is one of these targets, but the work 
of Kupas et al. (2011) provides a strong 
rationale for further studies to determine 
the biological significance of RANK 
expression on human melanoma cells.
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